Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan

被引：0
|
作者：
Goto, Y. [1 ]
Yamamoto, N. [2 ]
Masters, E. [3 ]
Kikkawa, H. [4 ]
Mardekian, J. [3 ]
Wiltshire, R. [5 ]
Togo, K. [4 ]
Ma, H. [6 ]
Ohe, Y. [1 ]
机构：
[1] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[2] Wakayama Med Univ, Dept Internal Med, Wakayama, Japan
[3] Pfizer Inc, New York, NY USA
[4] Pfizer Japan Inc, Tokyo, Japan
[5] Pfizer Inc, Tadworth, England
[6] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
ALK-positive NSCLC; treatment sequencing; tyrosine kinase inhibitor;
D O I：
10.1016/j.jtho.2018.08.1590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-30
引用
收藏
页码：S878 / S879
页数：2
相关论文
共 50 条
  • [21] Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer
    Imase, R.
    Endo, S.
    Sasahara, Y.
    Shinmura, T.
    Ozawa, T.
    Majima, H.
    Hara, T.
    Shimada, H.
    Yamauchi, S.
    Sakakibara, Y.
    Kobayashi, A.
    Yamazaki, K.
    Jin, Y.
    Yamanaka, K.
    Matsubara, O.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1953 - S1953
  • [22] Cytomorphology of Non-Small Cell Lung Carcinoma (NSCLC) with Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement
    Toll, A. D.
    Illei, P.
    Maleki, Z.
    MODERN PATHOLOGY, 2013, 26 : 104A - 104A
  • [23] Cytomorphology of Non-Small Cell Lung Carcinoma (NSCLC) with Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement
    Toll, A. D.
    Illei, P.
    Maleki, Z.
    LABORATORY INVESTIGATION, 2013, 93 : 104A - 104A
  • [24] Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer
    Yang, Junyi
    Gong, Weiliang
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (03) : 173 - 178
  • [25] Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
    Arbour, Kathryn C.
    Riely, Gregory J.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (01) : 101 - +
  • [26] Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer Patients Treated with Ensartinib
    Wakelee, H.
    Reckamp, K.
    Leal, T.
    Chiappori, A.
    Waqar, S.
    Zeman, K.
    Neal, J.
    Liang, C.
    Harrow, K.
    Holzhausen, A.
    Zhou, J.
    Selvaggi, G.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S566 - S566
  • [27] Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
    Singh, Abhay
    Chen, Hongbin
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 6615 - 6628
  • [28] Economic evaluation of crizotinib, alectinib, ceritinib, and brigatinib in treatment naive anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Choi, Briana
    Alkhatib, Nimer S.
    Halawah, Hala
    Calamia, Matthias
    Gulick, Dexter
    Manasrah, AlMothana
    Alkhdour, Odai
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] BUDGET IMPACT OF ALECTINIB IN THE TREATMENT OF NAIVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GREECE
    Kourkoulas, N.
    Kyriopoulos, D.
    Athanasakis, K.
    VALUE IN HEALTH, 2017, 20 (09) : A424 - A424
  • [30] Comparative analyses of overall survival of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who did not receive ALK inhibitors
    Kim, D.
    Lee, J. K.
    Park, H. S.
    Kulig, K.
    Kim, T. M.
    Lee, S.
    Jeon, Y.
    Chung, D. H.
    Heo, D. S.
    Kim, W. H.
    Bang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345